The TARGET BP Clinical Program

The TARGET BP OFF-MED Clinical Trial is also evaluating the Peregrine System Kit in patients who are either not taking anti-hypertension medications for elevated blood pressure or for patients whose anti-hypertension medications have been removed. Early studies^1-3 of the Peregrine Catheter using a neurolytic agent suggested the procedure can reduce blood pressure by deactivating specific nerves surrounding the renal (kidney) arteries that, through over-signaling, can contribute to high blood pressure.

The purpose of the trial is to investigate the safety and preliminary efficacy of the alcohol drug product when used for transcatheter alcohol-mediated renal denervation to treat patients with uncontrolled blood pressure while not taking anti-hypertensive medications. Participants include patients who do not take antihypertensive medication and those on 1-2 antihypertensive medications who will stop taking these medications for 3 months during the trial, in order to clearly evaluate the benefit of the procedure alone in managing high blood pressure.  The randomized, sham-controlled phase of the trial was followed by a crossover phase, where patients who were randomized to the sham control arm had the opportunity to receive active treatment. The randomized controlled phase is complete, and results have demonstrated that alcohol-mediated renal denervation is safe and modest blood pressure lowering has been achieved in the treatment arm at 2 months. Antihypertensive medication burden was lower in the renal denervation group through 12 months. The reduced medication burden observed in the renal denervation group, relative to the sham control group, may be due to better blood pressure control associated with renal denervation and a reduced need for medications. This observation suggests a renal denervation treatment effect and potential benefit for the patient up to 12 months post-procedure⁴. Subjects who entered the crossover arm are in final follow-up phase of the study.